Connection

Mark Kindy to Aspartic Acid Endopeptidases

This is a "connection" page, showing publications Mark Kindy has written about Aspartic Acid Endopeptidases.
Connection Strength

0.752
  1. The cysteine protease inhibitor, E64d, reduces brain amyloid-? and improves memory deficits in Alzheimer's disease animal models by inhibiting cathepsin B, but not BACE1, ?-secretase activity. J Alzheimers Dis. 2011; 26(2):387-408.
    View in: PubMed
    Score: 0.351
  2. Control of ?-Site Amyloid Precursor Protein-Cleaving Enzyme-1 Expression by Protein Kinase C-?/? and Nuclear Factor ?-B. Curr Alzheimer Res. 2021; 18(12):941-955.
    View in: PubMed
    Score: 0.176
  3. Deletion of the cathepsin B gene improves memory deficits in a transgenic ALZHeimer's disease mouse model expressing A?PP containing the wild-type ?-secretase site sequence. J Alzheimers Dis. 2012; 29(4):827-40.
    View in: PubMed
    Score: 0.094
  4. Pharmacogenetic features of cathepsin B inhibitors that improve memory deficit and reduce beta-amyloid related to Alzheimer's disease. Biol Chem. 2010 Aug; 391(8):861-72.
    View in: PubMed
    Score: 0.085
  5. Brain pyroglutamate amyloid-? is produced by cathepsin B and is reduced by the cysteine protease inhibitor E64d, representing a potential Alzheimer's disease therapeutic. J Alzheimers Dis. 2014; 41(1):129-49.
    View in: PubMed
    Score: 0.027
  6. High cholesterol-induced neuroinflammation and amyloid precursor protein processing correlate with loss of working memory in mice. J Neurochem. 2008 Jul; 106(1):475-85.
    View in: PubMed
    Score: 0.018
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.